Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell-signaling

In glioblastoma (GBM), the EGF receptor (EGFR) and Src family kinases (SFKs) contribute to an aggressive phenotype. EGFR may be targeted therapeutically; however, resistance to EGFR-targeting drugs such as Erlotinib and Gefitinib develops quickly. In many GBMs, a truncated form of the EGFR (EGFRvIII...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogene
Autors principals: Hu, Jingjing, Muller, Karra A., Furnari, Frank B., Cavenee, Webster K., VandenBerg, Scott R., Gonias, Steven L.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4411189/
https://ncbi.nlm.nih.gov/pubmed/25347738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2014.336
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars